Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV8-F8 is an adeno-associated virus serotype 8 (AAV8) vector-based gene therapy designed for the treatment of Hemophilia A. It carries a codon-optimized expression cassette for human coagulation Factor VIII (F8). The therapy aims to provide sustained expression of Factor VIII in the liver following a single intravenous administration, thereby reducing or eliminating the need for regular factor replacement therapy. Research conducted at the Children's Hospital of Philadelphia (CHOP) has focused on optimizing the size of the F8 expression cassette to improve packaging efficiency, virion homogeneity, and transgene expression levels, as oversized cassettes can lead to incomplete packaging and reduced efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AAV8-F8.